JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting
JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study.
LAS VEGAS, Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.
Dr. Amol Soin, Chief Medical Officer of JanOne, will present the results and noted that "This data shows that Jan101 may provide a non-opioid solution to treat diabetic neuropathy pain, but what was also quite exciting was that we saw improvement in nerve conduction velocity which may indicate that Jan101 may actually help the disease process by potentially improving nerve function. If proven further, this could be game changing for patients."
The Ohio Society of Interventional Pain Physicians annual meeting is a large regional pain management meeting from August 17 – 20th that draws attendance from physicians across the US. Diabetic neuropathy is an often-debilitating condition that is on the rise in the USA characterized by burning pain and numbness typically in the extremities. There currently are few to no effective treatments that show improvement in nerve conduction velocity.
"We look forward to presenting our data and telling the story of Jan101 which we feel may provide great therapeutic benefit to patients who suffer from diabetic neuropathy," said Tony Isaac, JanOne's CEO.
Forward Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the statements that JAN101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope" "should", "would", "may", "potential" and other similar expressions. Such statements reflect JanOne's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by JanOne, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause JanOne's actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC").
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in JanOne's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and JanOne does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. JanOne cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
About JanOne Inc.
JanOne is a unique Nasdaq-listed company offering innovative, actionable solutions that it believes can help create an end to the opioid crisis. JanOne is dedicated to funding resources toward innovation, technology and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and widespread in the country's history. The company recently sold its legacy business – ARCA Recycling – under its current brand name. JanOne's subsidiary, ARCA Recycling, recycled household appliances by providing turnkey recycling and replacement services for utilities and other sponsors of energy efficiency programs.
Please visit www.janone.com for additional information.
Media Contact
Investor Relations
IR@janone.com
1-800-400-2247
View original content to download multimedia:https://www.prnewswire.com/news-releases/janone-to-present-prior-phase-ii-data-on-diabetic-neuropathy-at-the-ohio-society-of-interventional-pain-physicians-annual-meeting-301904684.html
SOURCE JanOne Inc.
